30 Quotes by John Rother

Shifting to private investment wouldn't be easy. A whole generation would have to pay twice -- saving for themselves while paying benefits to those retired under the old system.

Of course, these trends are playing out differently across the states. Florida, for example, has already experienced a demographic wave that illustrates the need for timely changes in state programs.

Right now, it seems to be relatively quiet. For people (who are enrolled in the program), it's actually working.

If only 20 percent or even 30 percent of seniors sign up, that is every negative for the future of the program because the people most likely to sign up are the people with high drug expenses, and you don't have insurance if you don't spread the risk among people who are healthy.

What we find is that these price increases are pretty much across the board -- it doesn't seem to make much difference what category of drug is involved or what manufacturer. Obviously, those people that are chronically ill, and particularly those who suffer from more than one chronic illness, they are getting hit pretty hard.

I think the industry is more concerned about shareholders than they are about the patients who take the pills.

State and federal policymakers should seize the rare opportunity afforded by positive demographic, socioeconomic, and health trends to make essential changes in the nation's long term care programs.

It doesn't seem at this point that there's likely to be legislation moving on to the president. I think our job is mostly done.

That was a real surprise. Generic drug prices have been kept down substantially compared to previous years. I'm not sure I can explain that, but it's certainly good news for consumers and more reason than ever to switch to a generic drug if you have that option.